Table 4

Treatment responses and follow-up data based on induction therapies

Total (n=49)MMF group (n=20)CYC group (n=18)The other-regimens group (n=11)p Value*
Follow-up time, months100.17 (51.82–186.20)149.88 (97.47–191.53)96.35 (25.36–169.06)81.60 (34.90–119.90)0.114
Treatment response
Complete remission22 (44.90)13 (65.00)3 (16.67)6 (54.55)0.004
Partial remission27 (55.10)15 (75.00)6 (33.33)6 (54.55)0.021
Total remission27 (55.10)15 (75.00)6 (33.33)6 (54.55)0.021
Renal relapse8 (29.63)5 (33.33)2 (33.33)1 (16.67)0.900
Clinical data at the last follow-up
SLEDAI, score2 (0–6)2 (0–4)4 (2–11)2 (0–5)0.015
Proteinuria, g/24 hours0.39 (0.79–1.06)0.28 (0.13–0.49)1.06 (0.43–3.53)0.25 (0.18–0.49)0.001
Urinary RBC count, ×104/mL1 (1–6)1 (1–5)5 (1–51)1 (1–2)0.083
SAlb, g/L41.00 (36.00–44.10)43.50 (39.18–45.10)35.75 (33.13–42.05)43.1 (40.75–45.25)0.013
SCr, μmol/L76.02 (54.80–113.15)68.95 (53.26–91.72)109.17 (74.92–260.12)50.39 (42.43–71.16)0.011
Adverse events
Infection29 (59.18)12 (60.00)12 (66.67)5 (45.45)0.671
Arthralgia9 (18.37)3 (15.00)3 (16.67)3 (27.27)0.900
Arthrosis necrosis2 (4.08)0 (0.00)2 (11.11)0 (0.00)0.218
Menstrual disorder or menolipsis10 (20.41)6 (30.00)3 (16.67)1 (9.09)0.454
Cardiac vascular disease0 (0.00)0 (0.00)0 (0.00)0 (0.00)0.900
Tumour1 (2.04)0 (0.00)0 (0.00)1 (9.09)0.900
Epilepsy2 (4.08)1 (5.00)1 (5.56)0 (0.00)0.900
  • Values are given as n (%) or median (IQR).

  • *Comparison of MMF with CYC in the treatment of ANCA-positive LN patients.

  • CYC, cyclophosphamide; MMF, mycophenolate mofetil; RBC, red blood cell; SAlb, serum albumin; SCr, serum creatinine; SLEDAI, systemic lupus erythematosus disease activity index.